NAD+ in Parkinson’s: A Trial Result Nobody Saw Coming

For the better part of a decade, NAD+ boosters have been the supplement world’s golden children — the capsules longevity fans take daily. Nobody expected the first large, year-long clinical trial to end with the placebo group on top.

The trial that humbled a hype category

The study, called NOPARK, was run at 11 centres in Norway and coordinated by the clinical trials unit at Haukeland University Hospital. Of 537 people screened, 410 were randomized — average age about 66, a third women, all within two years of a Parkinson diagnosis and on stable standard medication.

The scoreboard was the MDS-UPDRS, a standard scale covering daily-life function and motor symptoms (parts I–III, scored 0–236, higher meaning worse). After a year, the NR group had worsened by 2.45 points on average; the placebo group had actually improved by 0.27 points. The adjusted difference of 2.72 points was statistically significant (P=.02) — in favour of placebo. Perspective matters here: doctors generally consider a change of roughly 5–7 points meaningful, so the gap sits below that line. Real, but modest.

Of five key secondary measures, four showed no significant difference — including the motor-exam score and a brain-imaging measure of dopamine function. The fifth was the non-motor symptom scale (mood, sleep, digestion, and friends), where the NR group worsened more than placebo (a 4.22-point difference, P=.009). The authors’ conclusion was blunt: the findings do not support nicotinamide riboside as a disease-modifying treatment for Parkinson disease.

Why researchers were so optimistic

This trial didn’t come out of nowhere — it was built on genuinely exciting groundwork. In animal models, NR showed protective effects on dopamine neurons, with better survival and motor behaviour. Early human infusions of NAD itself reported apparent improvements, though those studies had no placebo group. Then came two short randomized trials: NADPARK (500 mg twice daily, 30 days) raised brain NAD levels, shifted brain metabolism, and lowered inflammatory markers in spinal fluid; NR-SAFE (1,500 mg twice daily, four weeks) was well tolerated and boosted systemic NAD metabolism. Both hinted at small symptom improvements.

So the obvious next step was a long, large trial — and biology promptly reminded everyone why we do them. The authors noted the placebo group actually improved slightly, probably because everyone’s standard medication was carefully optimized during screening. And short-term biology doesn’t guarantee long-term outcomes: raising NAD levels in the brain over a month is one thing; changing the course of a disease over a year is another. It’s a useful lesson for the whole NAD+ category — more of a molecule isn’t automatically better.

What this means if you buy NAD+ boosters

First, a Canadian angle: NR and NAD+ capsules are sold in Canada as natural health products — licensed ones carry an eight-digit NPN on the label. This trial doesn’t say NR is dangerous (side-effect rates matched placebo), but it does deflate the grandest idea behind megadose NAD+ boosters: that more cellular NAD+ automatically translates into better outcomes. The paper also discloses that the supplement and placebo were supplied by the company that manufactures the NR ingredient — even a manufacturer-supported design couldn’t make the outcome flattering for NR.

This trial studied people with early Parkinson disease, not healthy adults — it isn’t proof of harm. But it is the strongest evidence yet that NAD+ boosters are not magic, and that the distance between a promising one-month biomarker study and real-world benefit is measured in years.

What is nicotinamide riboside and how is it supposed to work?

Nicotinamide riboside is a form of vitamin B3 (niacin) that the body converts into NAD+ — nicotinamide adenine dinucleotide, a coenzyme involved in energy production inside mitochondria and in DNA repair processes. It occurs naturally in trace amounts in some foods. NAD+ levels decline with age, which is why the “replenish it” pitch has been so seductive.

The forms matter, because the label can be confusing. Niacin (nicotinic acid) is the classic B3 form and the one famous for flushing; nicotinamide is the other classic form, with fewer side effects according to the NIH Office of Dietary Supplements; nicotinamide riboside is sold as its own distinct form; and NMN (nicotinamide mononucleotide) is a different precursor with far less human trial data.

What are the side effects of nicotinamide riboside?

In the NOPARK trial, overall side effects did not differ significantly between NR and placebo (rate ratio 0.85, P=.18). Serious adverse events occurred in 8.3% of the NR group versus 14.1% of the placebo group — actually fewer with the supplement, and shorter trials have likewise called NR well tolerated.

For the closest classic form, nicotinamide, the NIH notes that doses of 500 mg/day or more can cause diarrhea and easy bruising, and that doses of 3,000 mg/day or more can cause nausea, vomiting, and liver damage. The honest gap: long-term safety data at megadose levels are still limited. This year-long trial is the biggest data point yet — it doesn’t flag danger, but it doesn’t bless megadosing either. Pregnant or nursing women, people with liver issues, and anyone on medication should check with a professional before trying NR.

How much nicotinamide riboside should you take?

Research doses so far: 500 mg twice daily (NADPARK for 30 days; NOPARK for 52 weeks) and 1,500 mg twice daily (NR-SAFE for four weeks). There is no official recommended dose of NR for any purpose. For context, the daily requirement for vitamin B3 itself is tiny — 16 mg for adult men and 14 mg for women — while research NR doses run hundreds of times higher.

The big lesson of NOPARK: more is not better. A full year of 1,000 mg a day didn’t just fail to help — the supplement group went the wrong way on the main scale. If you take NR, follow the product label and resist the urge to megadose.

What should you look for on the label?

A valid NPN — an eight-digit number on the label means the product is licensed as a natural health product in Canada. The right form: look for “nicotinamide riboside” (often sold as the chloride salt), not niacin or nicotinamide. Third-party testing is a plus, and the dose per capsule should be stated plainly — skip “proprietary blends” that hide the real amount.

Finally, read the claims with this trial in mind. Any product promising to slow aging or alter a disease’s course is overpromising — this trial is a case study in why glossy biomarker stories don’t always survive a year-long placebo-controlled test.

This article reports on recent health research and is for general information only — it isn’t medical advice and doesn’t replace your doctor, pharmacist, or another qualified professional. Study findings describe what researchers observed, not a promise of results, and nothing here claims any supplement can diagnose, treat, cure, or prevent a disease. These statements have not been evaluated by Health Canada. Check with a healthcare professional before starting any new supplement, especially if you’re pregnant, nursing, taking medication, or managing a health condition.